ENGLEWOOD, Colo., Oct. 23,
2020 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI),
an innovative medical technology company specializing in the
manufacture and sale of non-invasive medical devices for pain
management, stroke rehabilitation, cardiac monitoring and
neurological diagnostics today announced that it has hired
Neil Friery as the President and
Chief Operating Officer (COO) of its Monitoring Solutions Division.
As President and COO, Neil will lead operations, sales, marketing
and product development of the Monitoring Solution Division
including the production and launch of the CM-1500 Blood Volume
Monitor which was granted 510(k) clearance by the U.S. Food and
Drug Administration earlier this year.
Thomas Sandgaard, founder and CEO
said: "I am excited to bring Neil in to run our Monitoring
Solutions Division. We continue to build out this division, adding
personnel in clinical research and sales and marketing. With Neil's
background, I am confident we will soon have our technology become
the standard-of-care for early detection of internal bleeding in
surgical and post-surgical recovery. While the CM-1500 is
already in full production, the next generation (CM-1600) is well
under way and we hope to apply for FDA clearance for that model
soon."
Neil Friery previously worked as
a Senior Vice President and General Manager at Zimmer Biomet,
leading the Surgical Division of this Fortune 500 musculoskeletal
healthcare company. During his tenure at Zimmer Biomet, Neil
oversaw all functional aspects of the Surgical organization and was
instrumental in the build-out of a direct sales force, several new
product launches, as well as strategic acquisitions and
distribution agreements doubling the division's revenue to
$400M. Prior to his appointment as
Senior Vice President and General Manager, Neil was the Director of
Finance for the Surgical Division.
Neil graduated with honors from the University of Notre Dame with a Bachelor of
Business Administration. Neil is currently an Entrepreneur in
Residence at Case Western Reserve
University and a member of the Board of Director's at the
West Side Catholic Center.
About Zynex
Zynex, founded in 1996, markets and sells its own design of
electrotherapy medical devices used for pain management and
rehabilitation; and the Company's proprietary NeuroMove device
designed to help recovery of stroke and spinal cord injury
patients. Zynex has also developed a blood volume monitor for use
in hospitals and surgery centers. For additional information,
please visit: Zynex.com.
Safe Harbor Statement
This release contains forward-looking statements within the
meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based only on
our current beliefs, expectations and assumptions regarding the
future of our business, future plans and strategies, projections,
forecasts, anticipated events and trends, the economy and other
future conditions. Because forward-looking statements
relate to the future, they are subject to inherent uncertainties,
risks and changes in circumstances that are difficult to predict
and many of which are outside of our control. Our actual results
and financial condition may differ materially from those indicated
in the forward-looking statements. Therefore you should not rely on
any of these forward looking statements. The Company makes no
express or implied representation or warranty as to the
completeness of forward looking statements or, in the case of
projections, as to their attainability or the accuracy and
completeness of the assumptions from which they are derived.
Factors that could cause actual results to materially differ from
forward-looking statements include, but are not limited to, the
need to obtain CE marking of new products, the acceptance of new
products as well as existing products by doctors and hospitals,
larger competitors with greater financial resources, the need to
keep pace with technological changes, our dependence on the
reimbursement for our products from health insurance companies, our
dependence on third party manufacturers to produce our goods on
time and to our specifications, implementation of our sales
strategy including a strong direct sales force, the impact of
COVID-19 on the global economy and other risks described in our
filings with the Securities and Exchange Commission including but
not limited to our Annual Report on Form 10-K for the year
ended December 31, 2019 as well as our quarterly reports
on Form 10-Q and current reports on Form 8-K.
Any forward-looking statement made by us in this release is
based only on information currently available to us and speaks only
as of the date on which it is made. We undertake no obligation to
publicly update any forward-looking statement, whether written or
oral, that may be made from time to time, whether as a result of
new information, future developments or otherwise.
Contact:
Zynex, Inc.
(800) 495-6670
Investor Relations Contact:
Amato and Partners, LLC
Investor Relations Counsel
admin@amatoandpartners.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/zynex-appoints-neil-friery-as-president-and-chief-operating-officer-of-monitoring-solutions-division-301158746.html
SOURCE Zynex